Surmodics (STU:SU6) Change In Working Capital : €-16.5 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Surmodics Change In Working Capital?

Surmodics's change in working capital for the quarter that ended in Jun. 2024 was €1.2 Mil.

Surmodics's change in working capital for the fiscal year that ended in Sep. 2023 was €-4.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Surmodics Change In Working Capital Historical Data

The historical data trend for Surmodics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Change In Working Capital Chart

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Working Capital

Get a 7-Day Free Trial

-9.03

0.95

-4.13

-12.40

-3.97

Surmodics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Working Capital	Get a 7-Day Free Trial															13.81	-9.06	-11.33	2.65	1.24

Surmodics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.5 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Surmodics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Surmodics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

SRDX:USA

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics Headlines

No Headlines